Methylation of [dna]{.smallcaps} is known to be an important mechanism of gene regulation. A hallmark of cancer is the deregulation of the [dna]{.smallcaps} methylation machinery and aberrant [dna]{.smallcaps} methylation patterns [@b1-co15_2p072]. In vertebrate genomes, a large fraction of the CG dinucleotide sequence is modified by methylation in gene-and tissue-specific patterns [@b2-co15_2p072]. Methylation of critical regulatory regions silences gene expression; loss of methylation is associated with gene activation [@b3-co15_2p072]. Because cancer progression requires many changes in the normal program of gene expression, it stands to reason that aberrations in [dna]{.smallcaps} methylation play a critical role in the changes in gene expression involved in cancer progression and metastasis.

Methylation changes in [dna]{.smallcaps} play a role very similar to that of genetic mutations in cancer; however, unlike a genetic alteration, [dna]{.smallcaps} methylation is potentially reversible with pharmacologic intervention. The [dna]{.smallcaps} methylation machinery was therefore proposed--- almost a decade and a half ago---to be an attractive anticancer target [@b4-co15_2p072].

BACKGROUND
==========

Three principal kinds of aberration in the [dna]{.smallcaps} methylation machinery occur in cancer:

-   Hypermethylation of tumour suppressor genes [@b5-co15_2p072]--[@b7-co15_2p072]

-   Aberrant expression of [dna]{.smallcaps} (cytosine-5-)-methyl-transferase 1 ([dnmt]{.smallcaps}1) and other [dnmt]{.smallcaps}s that methylate genomic [dna]{.smallcaps} involved in processes of gene inactivation, chromatin organization, X chromosome inactivation, and genomic imprinting

-   Hypomethylation of unique genes and repetitive sequences

These aberrations in [dna]{.smallcaps} methylation have very important diagnostic significance, and using current whole-genome techniques, the methylation signatures of specific cancer types are being delineated. These signatures will play an increasingly important role in diagnosis and prognosis of all cancers [@b8-co15_2p072].

The expression of [dnmt]{.smallcaps}1 is tightly regulated with the state of cell growth by transcriptional and posttranscriptional mechanisms [@b9-co15_2p072],[@b10-co15_2p072]. Several oncogenic pathways lead to overexpression of *DNMT1* [@b11-co15_2p072]. Overexpression of *DNMT1* in non-transformed cells causes cellular transformation, which supports the idea that inhibition of [dnmt]{.smallcaps}1 would block tumour growth [@b12-co15_2p072]. The anticancer effects of [dnmt]{.smallcaps}1 inhibition were demonstrated both pharmacologically, using antisense oligonucleotide inhibitors [@b13-co15_2p072],[@b14-co15_2p072], and genetically, using *dnmt1*--/-- mice [@b15-co15_2p072].

RATIONALE
=========

To properly design and apply therapeutic strategies that involve [dnmt]{.smallcaps}1 inhibition, it is essential to understand why [dnmt]{.smallcaps}1 transforms cells and why [dnmt]{.smallcaps}1 inhibition blocks tumour growth. The commonly accepted and attractively straightforward model is that [dnmt]{.smallcaps}1 inhibition causes loss of methylation during [dna]{.smallcaps} synthesis and therefore activation of tumour-suppressor genes that are silenced by [dna]{.smallcaps} methylation. Activation of tumour-suppressor genes by demethylation would be expected to block tumour growth. Another possible utility of demethylation agents is demethylation of tumour antigen promoters, which can lead to reactivation of the expression of those promoters, thus increasing the sensitivity of tumour cells to immunosurveillance.

If demethylation is the only mechanism of action of [dnmt]{.smallcaps}1 inhibitors, then the goal should be to develop catalytic inhibitors of the [dna]{.smallcaps} methylation reaction that would cause global demethylation of [dna]{.smallcaps}. However, there are several reasons to question whether [dnmt]{.smallcaps}1 inhibition blocks tumour growth exclusively through inhibition of [dna]{.smallcaps} methylation:

-   Knockdown of [dnmt]{.smallcaps}1 by small interfering [rna]{.smallcaps} (si[rna]{.smallcaps}) or antisense oligonucleotides blocks the growth of cancer cells by mechanisms independent of [dna]{.smallcaps} methylation through induction of tumour-suppressor genes [@b16-co15_2p072], triggering a [dna]{.smallcaps} damage response and inhibition of [dna]{.smallcaps} replication [@b17-co15_2p072].

-   The multifunctional protein [dnmt]{.smallcaps}1 has multiple domains. To be able to target the clinically relevant actions of [dnmt]{.smallcaps}1, delineating the functional domains of [dnmt]{.smallcaps}1 that are critical for cancer growth will be important [@b18-co15_2p072].

APPLICATIONS
============

Several clinical trials with a nucleoside analogue pan-[dnmt]{.smallcaps} inhibitor, 5-azacytidine (5-azaC), and its deoxy analogue, 5-deoxycytidine (5-azaCdR), a potent and non-selective [dna]{.smallcaps} methylation inhibitor, have been launched [@b19-co15_2p072]. In several clinical trials involving hematologic malignancies, especially myelodysplastic syndrome, several reports showed responses to 5-azaC with tolerable adverse effects [@b20-co15_2p072]. However, no significant success has been reported with solid tumours [@b21-co15_2p072]. The weak response of solid tumours might be the result of pharmacokinetic issues: delivery problems, or dosing and scheduling problems, or both. Various combination strategies involving 5-azaC and other chemotherapeutic agents, and other chromatin modifiers such as histone deacetylase inhibitors are now being tried [@b22-co15_2p072].

Although 5-azaC has been tested in clinical and preclinical settings for decades, basic questions remain regarding its mechanism of action. It is unclear whether the clinical activity of 5-azaC requires demethylation of candidate tumour-suppressor genes; whether the anticancer effect is a result of activities independent of [dna]{.smallcaps} methylation, mediated through 5-azaC binding of [dnmt]{.smallcaps}1 and other [dnmt]{.smallcaps}s; or whether the main activity of this agent relates to its non-specific toxicity as a nucleoside analogue. Similarly, the specific [dnmt]{.smallcaps}1 isoforms that are responsible for the anticancer activity of 5-azaC remain undefined.

These unresolved issues have implications for the dosing and scheduling of 5-azaC and for the development of new, more potent [dnmt]{.smallcaps} inhibitors. A major issue is the possibility that non-selective demethylation would induce pro-metastatic genes.

Recent trials have focused on low-dose 5-azaC (well below the maximum tolerated dose), under the supposition that 5-azaC causes demethylation at low doses but is mainly toxic at high doses [@b20-co15_2p072]. Those trials showed better responses; however, no immediate correlation was observed between the response past a given threshold and the extent of demethylation. Moreover, response was not correlated with the presence of a hypermethylated *p15* before treatment [@b20-co15_2p072].

Another nucleoside analogue that has recently been introduced to the arsenal of [dnmt]{.smallcaps} inhibitors is zebularine, a nucleoside analogue, which, unlike 5-azaC, is chemically stable and orally bioavailable. Zebularine was originally identified as a cytidine deaminase inhibitor [@b23-co15_2p072]. The compound exhibits [dna]{.smallcaps} demethylation activity with reduced potency and toxicity as compared with 5-azaC. Nevertheless zebularine belongs to the same class of nucleoside analogues, raising similar problems to those seen with 5-azaC.

It is unfortunate that the only drug targeting [dnmt]{.smallcaps}1 in the clinic is an "old" nucleoside analogue that must be incorporated into [dna]{.smallcaps} to perform its action. Thus, although the goal of [dna]{.smallcaps} methylation therapy is to target the cell's machinery in a way that is fundamentally different from classical chemotherapy and thus anticipated to exhibit limited toxicity, the use of a classical nucleoside analogue seems to defeat that purpose.

The many toxicities of 5-azaC result from its properties as a nucleoside analogue and might perhaps mask its activity on [dnmt]{.smallcaps}s. The only non-nucleoside, isotypic, specific [dnmt]{.smallcaps}1 inhibitor that has undergone clinical trial is MG98, a second-generation antisense oligonucleotide that specifically targets [dnmt]{.smallcaps}1 messenger [rna]{.smallcaps} [@b24-co15_2p072]. The mechanism of action of this latter class of inhibitors is different in many respects from that of the nucleoside-analogue catalytic inhibitors of [dnmt]{.smallcaps}1. With MG98, the expression of the [dnmt]{.smallcaps}1 protein is entirely eliminated, and thus all functional activities of [dnmt]{.smallcaps}1 are targeted, including methylation-independent activities. Knockdown of [dnmt]{.smallcaps}1 results in inhibition of [dna]{.smallcaps} replication [@b25-co15_2p072], triggering a damage response [@b17-co15_2p072] and inducing tumour-suppressor genes [@b16-co15_2p072]. The immediate blocking of replication by [dnmt]{.smallcaps}1 knockdown dramatically limits the demethylation induced by [dnmt]{.smallcaps}1 inhibition, thus avoiding the potential deleterious impact of global demethylation [@b17-co15_2p072].

The chief remaining issue with antisense oligonucleotides is their delivery to solid tumours. The clinical trials of this promising class of drugs were recently stopped because of a lack of objective response. Nevertheless, the overall strategy---and therapeutic si[rna]{.smallcaps}s--- carries great promise. Searching for agents that knock down [dnmt]{.smallcaps}1 rather than inhibit its catalytic activity is a priority that should be pursued.

CONCERNS AND IMPLICATIONS
=========================

Although the principal attention in the field of cancer has been directed at the phenomenon of hypermethylation, a hallmark of the methylation pattern in many tumours is hypomethylation [@b26-co15_2p072]. Recent data suggest that demethylation activates metastatic genes such as heparanase [@b27-co15_2p072] and urokinase plasminogen activator, and thus plays an important role in metastasis [@b28-co15_2p072]. That finding raises two important questions with critical therapeutic implications:

-   First, catalytic inhibitors of [dnmt]{.smallcaps}s (such as 5-azaC) that cause global hypomethylation and that are now used in anticancer therapy, might increase the propensity of cancer cells to metastasize.

-   Second, might demethylation inhibitors be a new approach to cancer therapy? It is therefore critical to develop [dnmt]{.smallcaps}1 inhibitors that do not cause demethylation of metastatic genes. A new goal in [dna]{.smallcaps} methylation therapy should be the development of [dna]{.smallcaps} demethylation inhibitors [@b26-co15_2p072].

Two different approaches were recently used to block demethylation in cancer. The first approach involved treatment with the methyl donor *S-*adenosylmethionine ([sam]{.smallcaps}). *S-*Adenosylmethionine contributes the methyl moieties to the methylation reactions and has also been shown to inhibit demethylase activity *in vitro* and in cells [@b29-co15_2p072]. Previously, [sam]{.smallcaps} was shown to be chemoprotectant in a liver cancer model in rodents [@b30-co15_2p072]. Treatment of human breast and prostate cancer cell lines *in vitro* with [sam]{.smallcaps} resulted in inhibition of invasion *in vitro,* and metastasis and tumour growth when the cells were transplanted into nude mice *in vivo.* The [sam]{.smallcaps} molecule is notoriously unstable [@b28-co15_2p072],[@b31-co15_2p072]. The results with this agent call for an effort to develop [sam]{.smallcaps} analogues with improved pharmacokinetics.

Another important line of investigation involves identifying the proteins responsible for demethylation of metastatic genes in cancer and targeting them for inhibition. One protein---methylated domain [dna]{.smallcaps} binding 2 (Mbd2)---was previously suggested to be involved in silencing methylated genes and demethylation alike [@b29-co15_2p072],[@b32-co15_2p072]. Blocking Mbd2 in breast and prostate cancer cell lines inhibits tumour growth, invasiveness, and metastasis *in vivo* [@b28-co15_2p072],[@b31-co15_2p072]. The *MBD2* antisense oligonucleotides, *MBD2* si[rna]{.smallcaps} inhibitors, and the Mbd2 antagonists are therefore potentially promising antimetastasis candidates.

SUMMARY
=======

The machinery of [dna]{.smallcaps} methylation and demethy-lation represents an attractive therapeutic target; however, certain questions need to be answered before the full potential of this approach is realized. The [dna]{.smallcaps} methylation inhibitor currently in use is crude and, by demethylation, could unleash pro-metastasis genes that might increase metastasis. The specific functions of [dnmt]{.smallcaps}1 that are involved in tumorigenesis must be isolated from the functions involved in metastasis. Not only [dnmt]{.smallcaps}s, but also the [dna]{.smallcaps} demethylation machinery, are emerging as new targets for inhibition of metastasis---one of the most intractable facets of cancer. The challenge is to design and target the various compartments of the [dna]{.smallcaps} methylation machinery to achieve both growth-control induction of tumour antigens and inhibition of metastasis in the absence of adverse effects on methylation.
